ReleaseWire Connect

Systemic Lupus Erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease which leads to weakening of the immune system. It results in systemic inflammation which affects multiple organs such as kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Acute Cutaneous Lupus, Chronic or Discoid Lupus, Lupus Panniculitis, Lupus Pernio, Subacute Cutaneous Lupus and Tumid Lupus are the most common form of Systemic Lupus Erythematosus.

Friedreich's Ataxia a rare inherited autosomal recessive disorder that causes nervous system damage and movement problems. It is caused by a mutation in a gene labeled frataxin (FXN). Over time this deficiency causes the aforementioned damage, as well as frequent fatigue due to effects on cellular metabolism. Friedreich's ataxia is the most common of the autosomal recessive ataxias.

DelveInsight is a leading Market Research and Business Consulting firm focused exclusively on life sciences. It supports companies by providing end to end comprehensive solutions to improve their performance and in making long-lasting decision for their businesses.

The Report "Natural Killer Cells Therapies - Competitive Landscape, Technology, and Pipeline Analysis, 2017" covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell-based therapies along with drugs that augment (enhance or activate) the NK cells. The Report provides in-depth analysis of the Natural Killer Cell-based therapies profiles along with the augmenting therapies covering their pre-clinical and clinical studies, collaborations details and deal values, Technologies and Targeted antigens. The Report provides the NK Cell-based therapies licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.

DelveInsight's Report, "Chimeric Antigen Receptor (CAR) T-cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2017" emphasizes on the currently active CAR-T cell products in research and development.

DelveInsight's, "Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017", the report provides comprehensive insights about microbiome based therapeutic pipeline products. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under this category.